Leukemia Posts - Page 2 of 71 on Medivizor

Evaluating treosulfan vs reduced-intensity busulfan conditioning for allogeneic hematopoietic cell transplantation in older patients with acute myeloid leukemia

Posted by Medivizor on Dec 31, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to compare the outcomes of allogeneic hematopoietic cell transplant (alloHCT) for older patients with acute myeloid leukemia (AML) using treosulfan (Trecondi) compared to reduced intensity busulfan (Myleran) conditioning. This study concluded that treosulfan conditioning appears to be more suitable for...

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Posted by Medivizor on Dec 31, 2022 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of zanubrutinib (Brukinsa) versus bendamustine (Treanda) plus rituximab (Rituxan) in untreated patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data showed that zanubrutinib significantly improved the survival without cancer worsening versus...

Evaluating the long-term effectiveness and safety of bosutinib versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia.

Posted by Medivizor on Dec 30, 2022 in Leukemia | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of bosutinib (Bosulif) versus imatinib (Gleevec) in patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML). The data showed that bosutinib had better effectiveness than imatinib in these patients. Some background CML is a type of cancer that starts...

Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.

$Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.$

Posted by Medivizor on Dec 4, 2022 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of time-limited treatment with ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL) by using minimal residual disease (MRD) guidance. The data showed that time-limited treatment with ibrutinib plus venetoclax...

Evaluating the long-term effectiveness of fixed-duration treatment with venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

$Evaluating the long-term effectiveness of fixed-duration treatment with venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.$

Posted by Medivizor on Nov 22, 2022 in Leukemia | 0 comments

In a nutshell This study evaluated the long-term effectiveness of fixed-duration treatment with venetoclax (Venclexta) plus rituximab (Rituxan) in patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). The data showed that fixed-duration treatment with venetoclax plus rituximab was effective over the long term in these...

A review of mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia

Posted by Medivizor on Oct 16, 2022 in Leukemia | 0 comments

In a nutshell This review aimed to assess the strength of previous evidence and to better understand the current role of SARS-CoV-2 vaccination in patients with chronic lymphocytic leukemia (CLL). This review concluded that there is an overall lower seroconversion rate for SARS-CoV-2 vaccination in these patients as compared with the general...

Combining anti-CD19 CAR T-cell therapy with ibrutinib for treating chronic lymphocytic leukemia

Posted by Medivizor on Sep 27, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to investigate if anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and ibrutinib (Imbruvica) could be combined for the treatment of patients with chronic lymphocytic leukemia (CLL). This study concluded that adding anti-CD19 CAR T-cell therapy (CART-19) to ibrutinib treatment in these patients...

Comparing salvage intensive chemotherapy and venetoclax combined with low-intensity regimens in patients with relapsed/refractory acute myeloid leukemia

$Comparing salvage intensive chemotherapy and venetoclax combined with low-intensity regimens in patients with relapsed/refractory acute myeloid leukemia$

Posted by Medivizor on Sep 27, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to compare salvage intensive chemotherapy (IC) and a venetoclax (Venclexta; VEN)-combined low-intensity regimen in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML). This study concluded that the VEN-combined regimen provided similar responses and survival rates when compared to...

Evaluating ponatinib treatment in any phase of treatment in patients with chronic myeloid leukemia resistant or intolerant to other tyrosine kinase inhibitors

Posted by Medivizor on Sep 18, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ponatinib (Iclusig) in patients with chronic myeloid leukemia (CML) who were resistant or intolerant to previous tyrosine kinase inhibitors (TKIs). This study concluded that ponatinib was effective in heavily pretreated patients when administered in any phase of...

Evaluating the long-term effectiveness of ibrutinib–rituximab treatment versus standard chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Posted by Medivizor on Sep 18, 2022 in Leukemia | 0 comments

In a nutshell This study investigated the long-term effectiveness of ibrutinib (Imbruvica)–rituximab (Rituxan) (IR) treatment versus standard chemoimmunotherapy (CIT) in patients aged 70 or younger with previously untreated chronic lymphocytic leukemia (CLL). The data showed that the IT regimen significantly improved the survival outcomes compared...

Evaluating outcomes after salvage therapy using chemotherapy or allogeneic stem cell transplantation for unresponsive acute myeloid leukemia

Posted by Medivizor on Sep 17, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of salvage treatment using either chemotherapy (CT) or allogeneic hematopoietic stem cell transplant (allo-HSCT) on the overall outcome in patients with refractory (unresponsive) acute myeloid leukemia (AML). This study concluded that allo-HSCT benefits these patients and that direct...

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Posted by Medivizor on Sep 1, 2022 in Leukemia | 0 comments

In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...

Leukemia Posts on Medivizor

Evaluating treosulfan vs reduced-intensity busulfan conditioning for allogeneic hematopoietic cell transplantation in older patients with acute myeloid leukemia

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Evaluating the long-term effectiveness and safety of bosutinib versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia.

Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.

Evaluating the long-term effectiveness of fixed-duration treatment with venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

A review of mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia

Combining anti-CD19 CAR T-cell therapy with ibrutinib for treating chronic lymphocytic leukemia

Comparing salvage intensive chemotherapy and venetoclax combined with low-intensity regimens in patients with relapsed/refractory acute myeloid leukemia

Evaluating ponatinib treatment in any phase of treatment in patients with chronic myeloid leukemia resistant or intolerant to other tyrosine kinase inhibitors

Evaluating the long-term effectiveness of ibrutinib–rituximab treatment versus standard chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Evaluating outcomes after salvage therapy using chemotherapy or allogeneic stem cell transplantation for unresponsive acute myeloid leukemia

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Categories

Recent Posts

Archives

Leukemia Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email